Analysts expect over 2017 rising revenue arGEN-X

Tomorrow the Belgian arGEN-X will report her past quarter's results. For this year arGEN-X's revenue will be around 34,57 million euros. This is according to the average of the analysts' estimates. This is hugely more than 2016's revenue of 14,71 million euros.

Historical revenues and results arGEN-X plus estimates 2017

The analysts expect for 2017 a net loss of 25 million euros. The majority of the analysts expects for this year a loss per share of 1,05 euros. The price-earnings-ratio equals -16,66.

For this year analysts don't expect the company to pay a dividend.The average dividend yield of the biotech companies equals a low 0,06 percent.

Newest target prices around 19 euros

The most recent recommendations for the biotech company are from DeGroof Petercam, KBC Securities and Wedbush Morgan Securities.

arGEN-X's market capitalization is based on the number of outstanding shares around 276,39 million euros.

Historical stock prices arGEN-X

On Tuesday, the stock closed at 17,49 euros.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.